We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · March 01, 2021

Outcomes of Systemic Targeted Therapy in Recurrent RCC Treated With Adjuvant Sunitinib

BJU International


Additional Info

Disclosure statements are available on the authors' profiles:

BJU International
Outcomes of Systemic Targeted Therapy in Recurrent Renal Cell Carcinoma Treated With Adjuvant Sunitinib
BJU Int 2021 Feb 06;[EPub Ahead of Print], G de Velasco, Á Ruiz-Granados, O Reig, F Massari, MA Climent Duran, E Verzoni, J Graham, R Llarena, M De Tursi, F Donskov, C Iglesias, HS Pandha, XG Del Muro, G Procopio, S Oudard, D Castellano, L Albiges

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading